# Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites

> **NCT01065246** · PHASE2 · COMPLETED · sponsor: **Neovii Biotech** · enrollment: 8 (actual)

## Conditions studied

- Malignant Ascites Due to Epithelial Carcinoma

## Interventions

- **DRUG:** catumaxomab

## Key facts

- **NCT ID:** NCT01065246
- **Lead sponsor:** Neovii Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2011-04
- **Final completion:** 2011-10
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2012-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01065246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01065246, "Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01065246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*